News
StockStory.org on MSN17h
MRNA Q1 Earnings Call: Management Focuses on Cost Reductions and Pipeline Progress Amid Revenue ShortfallBiotechnology company Moderna (NASDAQ:MRNA) in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The ...
Learn more about whether Kymera Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback